Quick Answer
Petros Pharmaceuticals, Inc. reported R&D Expense of $2.62 million for fiscal year 2024.
Petros Pharmaceuticals, Inc. R&D Expense — Annual History
| Fiscal Year | R&D Expense | YoY Change |
|---|---|---|
| 2024 | $2.62M | +8.5% |
| 2023 | $2.41M | +38.4% |
| 2022 | $1.74M | -2.7% |
| 2021 | $1.79M | +289.1% |
| 2020 | $459.6K | — |
Quarterly R&D Expense
| Quarter Ending | R&D Expense | YoY | QoQ |
|---|---|---|---|
| September 30, 2024 | $588.4K | +51.2% | +59.5% |
| June 30, 2024 | $368.8K | -57.4% | -76.3% |
| March 31, 2024 | $1.56M | +387.6% | +299.9% |
| September 30, 2023 | $389.1K | -47.1% | -55.1% |
| June 30, 2023 | $866.6K | +105.7% | +171.6% |
| March 31, 2023 | $319.1K | -21.3% | -56.6% |
| September 30, 2022 | $735.9K | +162.3% | +74.7% |
| June 30, 2022 | $421.2K | -15.8% | +3.9% |
- Petros Pharmaceuticals, Inc. showed an increase of +8.5% in R&D Expense compared to the prior fiscal year.
- Over the 2020–2024 period, Petros Pharmaceuticals, Inc.’s r&d expense has grown by 468.9% (from $459.6 thousand to $2.62 million).
- The most recent figure is from Petros Pharmaceuticals, Inc.’s fiscal year 2024 report (Form 10-K), filed with the SEC on March 31, 2025.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: